Medical Genetics

The Molecular Genetic Test Report and Biology

At a Glance

DEND syndrome usually results from a change in KCNJ11 or ABCC8 that keeps insulin-control channels open. This reduces insulin release and can disrupt brain signaling. A complete genetic report names the change, classifies it, and shows whether it was inherited or arose spontaneously.

Understanding DEND syndrome requires looking at the “blueprint” of the cells. Because this condition is caused by a specific genetic change, the most important document for identifying the cause of the disease is the molecular genetic test report ^[1]. This page explains the biological mechanism that causes DEND and what you should look for on that testing report.

The Biological “Glitch”: Overactive Gates

In a typical body, the pancreas uses tiny portals called KATP channels to decide when to release insulin. You can think of these channels as electrical gates that must close to signal the body to release insulin ^[2].

These gates are made of two main parts, each built by a different gene:

Kir6.2 (built by the KCNJ11 gene)
SUR1 (built by the ABCC8 gene) ^[2]^[3]

In a person with DEND, a mutation in one of these genes causes the gates to become activating or “gain-of-function.” This means the gates stay stuck in the “open” position ^[4]. Because the gates won’t close, the pancreas never gets the signal to release insulin into the blood, leading to permanent neonatal diabetes ^[5].

Crucially, these same gates are also found in the brain ^[6]. When these gates stay open in brain cells, it disrupts the normal electrical patterns needed for movement and learning, which contributes to the developmental delays and seizures seen in DEND ^[7]^[8].

How It Happens: Inheritance vs. De Novo

When families hear “genetic,” they often assume they passed the condition down. While familial transmission occurs, it is not the only way the syndrome develops.

De Novo Mutations: Most cases of DEND are de novo, meaning the genetic change happened spontaneously in the sperm or egg just before conception, or very early in development ^[9]^[10]. In these cases, the parents do not have the mutation in their own blood cells.
Inherited Mutations: Sometimes, a parent may carry the mutation and pass it on. In some cases, the parent might have a very mild version of the condition (like adult-onset diabetes) or no obvious symptoms at all ^[11].

Recurrence Risk: Doctors usually recommend testing both parents to understand the pattern. Even if both parents test negative, a de novo result lowers but does not entirely eliminate the recurrence risk for future pregnancies due to the possibility of germline mosaicism (where a small number of a parent’s reproductive cells carry the mutation undetected) ^[1]. A genetics professional should provide family-specific risk counseling.

Your Genetic Report Completeness Checklist

A genetic testing report contains complex data. To be useful, it should clearly list:

Item	What It Means
Gene Name	Usually KCNJ11 or ABCC8 ^[1].
Variant Name	Often looks like “p.Val59Met” (p.-level) or “c.175G>A” (c.-level). This indicates the exact “misspelling” in the DNA ^[3].
Zygosity	Usually “Heterozygous,” meaning one copy of the gene is affected ^[9].
Classification	Should be labeled Pathogenic or Likely Pathogenic. A Variant of Uncertain Significance (VUS) means the lab is not sure if the mutation causes disease, and a VUS should not be used alone to make treatment decisions ^[12].
Functional Data	Note that standard lab reports often do not contain functional evidence or state sulfonylurea sensitivity. The absence of this data does not mean the treatment won’t work ^[13]. Treatment response is interpreted by an expert team using published evidence and a supervised clinical trial.

If your results are “negative” but the child has symptoms, the doctor may need to order specialized testing for “look-alike” conditions like 6q24 methylation abnormalities, which require different assay techniques ^[14].

Common questions in this guide

Which genes are linked to DEND syndrome?

DEND syndrome is most often linked to activating changes in KCNJ11 or ABCC8. These genes help build KATP channels in pancreatic and brain cells; changes that keep the channels open can reduce insulin release and disrupt brain signaling.

What information should a DEND genetic test report include?

A report should identify the gene, the exact DNA and protein-level variant, whether one or both gene copies are affected, and the laboratory classification. It should also state whether the finding is pathogenic, likely pathogenic, or a variant of uncertain significance.

What does a VUS mean on a DEND genetic report?

A variant of uncertain significance, or VUS, is a gene change that the laboratory cannot yet classify as disease-causing or harmless. A VUS should not be used by itself to make treatment decisions, and its meaning may be reassessed as more evidence becomes available.

If neither parent has the DEND mutation, can it happen again in a future pregnancy?

Many DEND cases are de novo, meaning the change arose spontaneously and is not found in a parent’s blood sample. A negative parental test lowers the chance of recurrence but does not eliminate it because germline mosaicism can leave the change in a small number of reproductive cells.

Can a genetic report show whether sulfonylureas will work?

Standard genetic reports often do not include functional evidence or a statement about sulfonylurea sensitivity. The absence of that information does not prove the treatment will fail; an expert team uses published evidence and a supervised clinical trial to assess response.

What should be tested if genetic results are negative?

If testing does not identify a relevant DEND-related change, clinicians may consider specialized testing for look-alike conditions, including 6q24 methylation abnormalities and changes in genes such as INS. These findings may require different laboratory methods than a standard gene panel.

Get notified when new evidence is published on DEND syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (14)

1
The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study.
De Franco E, Flanagan SE, Houghton JA, et al.
Lancet (London, England) 2015; (386(9997)):957-63.
PMID: 26231457
2
New insights into KATP channel gene mutations and neonatal diabetes mellitus.
Pipatpolkai T, Usher S, Stansfeld PJ, Ashcroft FM
Nature reviews. Endocrinology 2020; (16(7)):378-393 doi:10.1038/s41574-020-0351-y.
PMID: 32376986
3
Sulfonylurea-Insensitive Permanent Neonatal Diabetes Caused by a Severe Gain-of-Function Tyr330His Substitution in Kir6.2.
McClenaghan C, Rapini N, De Rose DU, et al.
Hormone research in paediatrics 2022; (95(3)):215-223 doi:10.1159/000521858.
PMID: 34999583
4
ATP-Sensitive Potassium Channels in Hyperinsulinism and Type 2 Diabetes: Inconvenient Paradox or New Paradigm?
Nichols CG, York NW, Remedi MS
Diabetes 2022; (71(3)):367-375 doi:10.2337/db21-0755.
PMID: 35196393
5
Cryo-electron microscopy structures and progress toward a dynamic understanding of KATP channels.
Puljung MC
The Journal of general physiology 2018; (150(5)):653-669 doi:10.1085/jgp.201711978.
PMID: 29685928
6
KATP channel mutation disrupts hippocampal network activity and nocturnal gamma shifts.
Burkart ME, Kurzke J, Jacobi R, et al.
Brain : a journal of neurology 2024; (147(12)):4200-4212 doi:10.1093/brain/awae157.
PMID: 38748482
7
Developmental defects and impaired network excitability in a cerebral organoid model of KCNJ11 p.V59M-related neonatal diabetes.
Dalgin G, Tryba AK, Cohen AP, et al.
Scientific reports 2021; (11(1)):21590 doi:10.1038/s41598-021-00939-7.
PMID: 34732776
8
Patients with KCNJ11-related diabetes frequently have neuropsychological impairments compared with sibling controls.
Carmody D, Pastore AN, Landmeier KA, et al.
Diabetic medicine : a journal of the British Diabetic Association 2016; (33(10)):1380-6 doi:10.1111/dme.13159.
PMID: 27223594
9
Novel perspectives of super-high dose sulfonylurea and high-dose oral prednisolone in an infant with DEND syndrome due to V64M heterozygote KCNJ11 mutation.
Barash G, Bassan H, Livne A, et al.
Acta diabetologica 2021; (58(12)):1665-1672 doi:10.1007/s00592-021-01763-1.
PMID: 34272607
10
A novel de novo mutation at the ABCC8 gene in a newborn with transient diabetes mellitus.
Bolu S, Bucak İH, Konca Ç, et al.
Turk pediatri arsivi 2020; (55(2)):195-198 doi:10.14744/TurkPediatriArs.2019.01336.
PMID: 32684766
11
Comparison of diabetes phenotype in children and their mothers with permanent neonatal diabetes mellitus carrying the same KCNJ11 variants.
Stanik J, Barak L, Dankovcikova A, et al.
Endocrine regulations 2020; (54(4)):260-265 doi:10.2478/enr-2020-0029.
PMID: 33885251
12
Monogenic Neonatal Diabetes: Clinical Presentations, Genetic Findings, and Response to Therapy in a Retrospective Case Series.
Yakine F, Bouarab I, Alaoui-Inboui FZ, et al.
Cureus 2026; (18(1)):e102578 doi:10.7759/cureus.102578.
PMID: 41769619
13
Functional characterization of activating mutations in the sulfonylurea receptor 1 (ABCC8) causing neonatal diabetes mellitus in Asian Indian children.
Balamurugan K, Kavitha B, Yang Z, et al.
Pediatric diabetes 2019; (20(4)):397-407 doi:10.1111/pedi.12843.
PMID: 30861254
14
Molecular and clinical characteristics of monogenic diabetes mellitus in southern Chinese children with onset before 3 years of age.
Lin Y, Sheng H, Ting TH, et al.
BMJ open diabetes research & care 2020; (8(1)) doi:10.1136/bmjdrc-2020-001345.
PMID: 32792356

This page explains DEND syndrome biology and genetic test reports for informational purposes only and does not replace medical advice. A genetic counselor and your child’s care team should interpret the results and guide testing or treatment decisions.